Boehringer Ingelheim inaugurated its new China R&D Center in Shanghai’s innovation hub Zhangjiang today, marking a new phase in its local R&D operations. The center will expand early-stage clinical development, deepen external innovation ties, and accelerate the development of innovative treatments for patients worldwide.